Similar articles

• A demonstration of the ability of apomorphine to act on dopamine receptors on nerve terminals in the nucleus accumbens to reduce locomotor hyperactivity [proceedings].

  Costall B, Hui SC, Naylor RJ. Costall B, et al. Br J Pharmacol. 1979 Nov;67(3):475P-476P. Br J Pharmacol. 1979. PMID: 497587 Free PMC article. No abstract available.
• Cholinergic potentiation of neuroleptic effects in the nucleus accumbens.

  Vance MA, Blumberg JB. Vance MA, et al. Res Commun Chem Pathol Pharmacol. 1983 May;40(2):345-8. Res Commun Chem Pathol Pharmacol. 1983. PMID: 6136070
• On the structural requirements for dopamine-like activity in homogenates of rat nucleus accumbens [proceedings].

  Munday KA, Poat JA, Watling KJ, Woodruff GN. Munday KA, et al. Br J Pharmacol. 1977 Sep;61(1):150P-151P. Br J Pharmacol. 1977. PMID: 912199 Free PMC article. No abstract available.
• Activation of accumbal and striatal dopamine autoreceptors by some ergoline derivatives.

  Gundlach AL, Christie MJ, Beart PM. Gundlach AL, et al. Res Commun Chem Pathol Pharmacol. 1985 Apr;48(1):149-52. Res Commun Chem Pathol Pharmacol. 1985. PMID: 3992029
• Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens.

  Rouillon C, Degoulet M, Chevallier K, Abraini JH, David HN. Rouillon C, et al. Brain Res. 2008 Mar 10;1198:44-54. doi: 10.1016/j.brainres.2008.01.025. Epub 2008 Jan 18. Brain Res. 2008. PMID: 18261716